Syntara Interim Phase II Data SNT 5505,,,, SH Predictions......, page-22

The first Ph2 trial patient for SNT-5505 was dosed in December 2023. By March next year (still Q1 2025) SNT will have another +3 months of data since the announcement you reference, and nearly 16 months of data since the trial's inception, so I don't see it as necessarily meaning SNT won't talk to the FDA concerning study design until H2 2025. In fact, in March 2025, with the trial having only 5 months to go after running for 16 months, I think they may have more than enough to start talking with the FDA.